

Special Issue

New Advances in Cancer Immunotherapy

Message from the Guest Editor

The first use of immunotherapy against cancer emerged with the use of a mixture of bacterial toxins derived from the species of *Streptococcus pyogenes* and *Serratia marcescens* called Coley's toxin in sarcoma patients. Recent advances in therapy, such as PROTAC molecules, which target intracellular proteins involved in cancer development, mRNA vaccines, and enhanced CAR-T cell therapies, alongside continued development of checkpoint inhibitors and personalized vaccines, aim to improve efficacy, overcome resistance, and broaden the applicability of immunotherapy across various cancer types. This Special Issue addresses these therapies and includes a new form of tumor-infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, to improve treatment effectiveness.

Guest Editor

Dr. Vijay Kumar

Laboratory of Tumor Immunology and Immunotherapy, Department of Surgery Morehouse, School of Medicine Atlanta, Atlanta, GA 30310, USA

Deadline for manuscript submissions

28 February 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/251332

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).